Word

PHENOTYPE LOCK

Status

Pending

Status Code

686

Status Date

Tuesday, March 19, 2024

Serial Number

97388990

Mark Type

4000

Filing Date

Friday, April 29, 2022

Published for Opposition

Tuesday, March 19, 2024

Trademark Owner History

Quell Therapeutics Limited - Owner At Publication

Classifications

40 Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

5 Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection

1 Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry

Trademark Events

Mar 19, 2024

Official Gazette Publication Confirmation E-Mailed

Mar 19, 2024

Published For Opposition

Feb 28, 2024

Notification Of Notice Of Publication E-Mailed

Feb 28, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 15, 2024

Approved For Pub - Principal Register

Feb 15, 2024

Examiner's Amendment Entered

Feb 15, 2024

Notification Of Examiners Amendment E-Mailed

Feb 15, 2024

Examiners Amendment E-Mailed

Feb 15, 2024

Examiners Amendment -Written

Nov 1, 2023

Notification Of Final Refusal Emailed

Nov 1, 2023

Final Refusal E-Mailed

Nov 1, 2023

Final Refusal Written

Nov 1, 2023

Teas/Email Correspondence Entered

Oct 31, 2023

Correspondence Received In Law Office

Oct 31, 2023

Teas Response To Office Action Received

Aug 15, 2023

Notification Of Non-Final Action E-Mailed

Aug 15, 2023

Non-Final Action E-Mailed

Aug 15, 2023

Non-Final Action Written

Jul 21, 2023

Previous Allowance Count Withdrawn

Jul 11, 2023

Withdrawn From Pub - Og Review Query

Jun 29, 2023

Electronic Record Review Complete

Jun 23, 2023

On Hold - Electronic Record Review Required

Jun 22, 2023

Approved For Pub - Principal Register

Jun 22, 2023

Examiner's Amendment Entered

Jun 22, 2023

Notification Of Examiners Amendment E-Mailed

Jun 22, 2023

Examiners Amendment E-Mailed

Jun 22, 2023

Examiners Amendment -Written

May 20, 2023

Teas/Email Correspondence Entered

May 19, 2023

Correspondence Received In Law Office

May 19, 2023

Teas Response To Office Action Received

Feb 27, 2023

Notification Of Non-Final Action E-Mailed

Feb 27, 2023

Non-Final Action E-Mailed

Feb 27, 2023

Non-Final Action Written

Feb 16, 2023

Assigned To Examiner

May 4, 2022

New Application Office Supplied Data Entered

May 3, 2022

New Application Entered